BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 22011244)

  • 1. Hypoxia activated prodrugs of a 9-aza-anthrapyrazole derivative that has promising anticancer activity.
    El-Dakdouki MH; Adamski N; Foster L; Hacker MP; Erhardt PW
    J Med Chem; 2011 Dec; 54(23):8224-7. PubMed ID: 22011244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-ones.
    Antonini I; Santoni G; Lucciarini R; Amantini C; Dal Ben D; Volpini R; Cristalli G
    J Med Chem; 2008 Feb; 51(4):997-1006. PubMed ID: 18232651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor potential of aza-bioisosterism in anthracenedione-based drugs.
    Sissi C; Palumbo M
    Curr Top Med Chem; 2004; 4(2):219-30. PubMed ID: 14754455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel N-oxide of naphthalimides as prodrug leads against hypoxic solid tumor: synthesis and biological evaluation.
    Yin H; Xu Y; Qian X; Li Y; Liu J
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2166-70. PubMed ID: 17331719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.
    Mansour OC; Evison BJ; Sleebs BE; Watson KG; Nudelman A; Rephaeli A; Buck DP; Collins JG; Bilardi RA; Phillips DR; Cutts SM
    J Med Chem; 2010 Oct; 53(19):6851-66. PubMed ID: 20860366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationships of 1,5-diazaanthraquinones as antitumour compounds.
    Avendaño C; Pérez JM; Blanco Mdel M; de la Fuente JA; Manzanaro S; Vicent MJ; Martín MJ; Salvador-Tormo N; Menéndez JC
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3929-32. PubMed ID: 15225700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of stable, water soluble radicals as potential anti-cancer agents.
    Lattmann E; Begum A; Plater MJ
    Drug Des Discov; 1999 Nov; 16(3):195-201. PubMed ID: 10624565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological activity of N-2,3-dihydroxypropyl-N-4-chlorobutyl nucleoside phosphoramidate prodrugs.
    Wu W; Borch RF
    Mol Pharm; 2006; 3(4):451-6. PubMed ID: 16889439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of hypoxic and acidic tumor environments with a cobalt(III) chaperone complex.
    Yamamoto N; Renfrew AK; Kim BJ; Bryce NS; Hambley TW
    J Med Chem; 2012 Dec; 55(24):11013-21. PubMed ID: 23199008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
    Radi M; Adema AD; Daft JR; Cho JH; Hoebe EK; Alexander LE; Peters GJ; Chu CK
    J Med Chem; 2007 May; 50(9):2249-53. PubMed ID: 17419604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regioselective synthesis and in vitro anticancer activity of 4-aza-podophyllotoxin derivatives catalyzed by L-proline.
    Shi C; Wang J; Chen H; Shi D
    J Comb Chem; 2010 Jul; 12(4):430-4. PubMed ID: 20503973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and one-electron reduction characteristics of radiation-activated prodrugs possessing two 5-fluorodeoxyuridine units.
    Tanabe K; Sugiura M; Ito T; Nishimoto S
    Bioorg Med Chem; 2012 Sep; 20(17):5164-8. PubMed ID: 22847019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of novel bis-anthraquinone derivatives and their biological evaluation as antitumor agents.
    Taher AT; Hegazy GH
    Arch Pharm Res; 2013 May; 36(5):573-8. PubMed ID: 23471561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity.
    Wang Y; Xin D; Liu K; Zhu M; Xiang J
    Bioconjug Chem; 2009 Dec; 20(12):2214-21. PubMed ID: 19950889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, DNA binding, and cytotoxicity studies of pyrrolo[2,1-c][1,4]benzodiazepine-anthraquinone conjugates.
    Kamal A; Ramu R; Tekumalla V; Khanna GB; Barkume MS; Juvekar AS; Zingde SM
    Bioorg Med Chem; 2007 Nov; 15(22):6868-75. PubMed ID: 17822905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and antiproliferative activity of 1,4-bis(dimethylamino)-9,10-anthraquinone derivatives against P388 mouse leukemic tumor cells.
    Jin GZ; Jin HS; Jin LL
    Arch Pharm Res; 2011 Jul; 34(7):1071-6. PubMed ID: 21811913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
    Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
    J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and in-vitro cytotoxicity evaluation of novel naphtindolizinedione derivatives, part II: improved activity for aza-analogues.
    Defant A; Guella G; Mancini I
    Arch Pharm (Weinheim); 2009 Feb; 342(2):80-6. PubMed ID: 19173337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between structure and antiproliferative activity of 1-azaflavanones.
    Kawaii S; Endo K; Tokiwano T; Yoshizawa Y
    Anticancer Res; 2012 Jul; 32(7):2819-25. PubMed ID: 22753743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on quinones. Part 44: Novel angucyclinone N-heterocyclic analogues endowed with antitumoral activity.
    Valderrama JA; Colonelli P; Vásquez D; González MF; Rodríguez JA; Theoduloz C
    Bioorg Med Chem; 2008 Dec; 16(24):10172-81. PubMed ID: 19013074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.